Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 40.00K | -183.00K | -81.00K | 0.00 | 0.00 |
EBITDA | -11.77M | -11.05M | -15.27M | 0.00 | 752.45K |
Net Income | -12.05M | -11.41M | -15.43M | -1.99M | -13.33M |
Balance Sheet | |||||
Total Assets | 9.00M | 9.81M | 9.41M | 864.62K | 2.05M |
Cash, Cash Equivalents and Short-Term Investments | 8.59M | 9.14M | 8.61M | 864.62K | 2.04M |
Total Debt | 0.00 | 0.00 | 1.00M | 0.00 | 0.00 |
Total Liabilities | 1.97M | 1.71M | 1.78M | 220.59K | 93.24K |
Stockholders Equity | 7.03M | 8.10M | 7.63M | 644.03K | 1.96M |
Cash Flow | |||||
Free Cash Flow | -9.02M | -8.27M | -6.67M | -1.85M | -387.31K |
Operating Cash Flow | -9.01M | -8.26M | -6.65M | -1.85M | -387.31K |
Investing Cash Flow | -9.00K | -14.00K | -19.00K | 0.00 | 0.00 |
Financing Cash Flow | 10.86M | 8.80M | 14.41M | 675.00K | 2.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | $6.56B | -1.65 | 0.45% | 6.25% | 14.92% | 10.98% | |
47 Neutral | $7.74M | ― | -233.04% | ― | -76.61% | 73.25% | |
45 Neutral | $4.69M | ― | -440.77% | ― | -7.72% | 99.54% | |
42 Neutral | $10.50M | ― | -195.48% | ― | -40.47% | 96.14% | |
40 Underperform | $6.86M | ― | -195.55% | ― | ― | 65.72% | |
― | $4.68M | ― | -23.45% | ― | ― | ― | |
37 Underperform | $7.57M | ― | -101.49% | ― | -19.81% | 93.32% |
On April 30, 2025, Autonomix Medical, Inc. announced positive outcomes from the initial phase of its first-in-human proof-of-concept trial for treating severe pancreatic cancer pain. The trial demonstrated significant pain reduction and improved quality of life, with 100% of patients achieving zero opioid use at 7 days post-procedure. Following these results, the company plans to expand its study to include additional visceral cancers and earlier-stage pancreatic cancer, potentially doubling its addressable market.
Spark’s Take on AMIX Stock
According to Spark, TipRanks’ AI Analyst, AMIX is a Neutral.
Autonomix Medical, Inc. scores low due to severe financial performance issues, characterized by zero revenue and negative cash flows, despite low debt levels. Technical analysis shows potential short-term momentum, but a longer-term downtrend persists. Valuation is the weakest, with negative earnings and no dividend yield. The lack of earnings call data means no immediate guidance to offset these challenges, resulting in a low overall score.
To see Spark’s full report on AMIX stock, click here.